Indoco Remedies Posts Quarterly Loss Amid One-Time Labour Code Impact and Higher Costs

The latest update is out from Indoco Remedies Limited ( (IN:INDOCO) ).

Indoco Remedies reported unaudited standalone financial results for the quarter and nine months ended 31 December 2025, showing net revenue from operations of ₹38,957 lakh for the quarter and ₹1,20,448 lakh for the nine-month period, with total income of ₹40,768 lakh for the quarter. Despite healthy top-line performance and an unmodified review opinion from its statutory auditors, the company posted a quarterly standalone loss before tax of ₹2,045 lakh and a net loss of ₹2,000 lakh, driven in part by higher finance costs, operating expenses and exceptional items. Exceptional items included income from licensing its trademarks as well as a loss on sale-and-leaseback of non-current assets and a one-time charge of ₹694 lakh arising from increased employee benefit liabilities due to implementation of India’s new labour codes, which raised gratuity and leave liabilities through a revised definition of wages. The board approved these results at its meeting on 3 February 2026, and management highlighted that the impact of labour law changes is non-recurring, with the company continuing to monitor regulatory developments, a factor that may influence future profitability and cost structures.

More about Indoco Remedies Limited

Indoco Remedies Limited is an Indian pharmaceuticals company focused on the manufacture and sale of pharmaceutical products, with operations serving both the domestic market and international geographies. The company’s business is reported as a single primary segment in pharmaceuticals, with a significant share of revenue generated from sales within India alongside a substantial and growing contribution from exports.

Average Trading Volume: 1,794

Technical Sentiment Signal: Sell

Current Market Cap: 20.05B INR

For detailed information about INDOCO stock, go to TipRanks’ Stock Analysis page.